BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28389313)

  • 1. Fabry Disease: An Uncommon Cause of Renal Failure.
    López PD; Andreias L; Astiazarán-Symonds E; Chalabi J
    Am J Med; 2017 Sep; 130(9):e389-e390. PubMed ID: 28389313
    [No Abstract]   [Full Text] [Related]  

  • 2. Synchronous presentation of monoclonal gammopathy and Fabry nephropathy; diagnostic renal biopsy obviates initiation of myeloma therapy.
    Pokuri VK; Xu B; Neppalli V; Czyzyk J; Berenji F; Holstein SA; McCarthy PL
    Ann Hematol; 2015 Jun; 94(6):1067-8. PubMed ID: 25666077
    [No Abstract]   [Full Text] [Related]  

  • 3. The management and treatment of children with Fabry disease: A United States-based perspective.
    Hopkin RJ; Jefferies JL; Laney DA; Lawson VH; Mauer M; Taylor MR; Wilcox WR;
    Mol Genet Metab; 2016 Feb; 117(2):104-13. PubMed ID: 26546059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosing Fabry disease--delays and difficulties within discordant siblings.
    Brady M; Montgomery E; Brennan P; Mohindra R; Sayer JA
    QJM; 2015 Jul; 108(7):585-90. PubMed ID: 23378663
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
    Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
    J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
    Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
    J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fabry disease: raising awareness of the disease among physicians.
    Carubbi F; Bonilauri L
    Intern Emerg Med; 2012 Oct; 7 Suppl 3():S227-31. PubMed ID: 23073862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prominent regression of corneal deposits in Fabry disease 16 years after initiation of enzyme replacement therapy.
    Koh S; Sakai N; Maeda N; Nishida K
    Acta Ophthalmol; 2018 Mar; 96(2):e255-e256. PubMed ID: 28834375
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
    Talbot AS; Lewis NT; Nicholls KM
    Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agalsidase alfa slows the decline in renal function in patients with Fabry disease.
    Feriozzi S; Schwarting A; Sunder-Plassmann G; West M; Cybulla M;
    Am J Nephrol; 2009; 29(5):353-61. PubMed ID: 18974635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac challenges in patients with Fabry disease.
    Weidemann F; Linhart A; Monserrat L; Strotmann J
    Int J Cardiol; 2010 May; 141(1):3-10. PubMed ID: 19720409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease - Vascular manifestations.
    Karetova D; Bultas J; Dostalova G; Palecek T; Kovarnik T; Golan L; Linhart A
    Vasa; 2010 May; 39(2):123-31. PubMed ID: 20464667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The neurological manifestations of Fabry disease. A review].
    Firsov KV; Kotov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating enzyme replacement therapy in fabry disease.
    Koskenvuo JW; Kantola IM
    Arch Intern Med; 2010 Mar; 170(6):573-4; author reply 574. PubMed ID: 20308647
    [No Abstract]   [Full Text] [Related]  

  • 15. [Consensus for the study and treatment of Fabry disease. GETER Foundation].
    García de Lorenzo A;
    Med Clin (Barc); 2011 Jul; 137(4):178-83. PubMed ID: 21529855
    [No Abstract]   [Full Text] [Related]  

  • 16. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
    Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
    Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fabry disease from the neurologist's point of view: is it a rare cause of strokes?].
    Marti-Martinez S; Climent V; Pampliega-Perez A; Martin-Estefania C; Leiva-Santana C
    Rev Neurol; 2015 Jan; 60(2):93-5. PubMed ID: 25583594
    [No Abstract]   [Full Text] [Related]  

  • 18. [Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].
    Mignani R; Feriozzi S; Carraro G; Martinelli F; Cianciaruso B
    G Ital Nefrol; 2009; 26(5):577-84. PubMed ID: 19802803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement therapy and Fabry nephropathy.
    Warnock DG; Daina E; Remuzzi G; West M
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and management of kidney involvement in Fabry disease.
    Warnock DG; West ML
    Adv Chronic Kidney Dis; 2006 Apr; 13(2):138-47. PubMed ID: 16580615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.